Galapagos NV (NASDAQ:GLPG) Receives Average Rating of “Strong Sell” from Brokerages

Shares of Galapagos NV (NASDAQ:GLPG) have been given a consensus recommendation of “Strong Sell” by the six brokerages that are currently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a sell recommendation and one has issued a hold recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $26.00.

A number of analysts have weighed in on GLPG shares. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Galapagos in a research note on Tuesday, August 5th. Wall Street Zen upgraded shares of Galapagos from a “sell” rating to a “hold” rating in a research note on Saturday, July 26th.

Institutional Trading of Galapagos

A number of large investors have recently made changes to their positions in the stock. EcoR1 Capital LLC grew its stake in shares of Galapagos by 569.0% in the second quarter. EcoR1 Capital LLC now owns 1,036,945 shares of the biotechnology company’s stock worth $29,024,000 after acquiring an additional 881,939 shares during the period. Vestal Point Capital LP grew its stake in shares of Galapagos by 11.1% in the first quarter. Vestal Point Capital LP now owns 200,000 shares of the biotechnology company’s stock worth $5,024,000 after acquiring an additional 20,000 shares during the period. Norges Bank bought a new stake in shares of Galapagos in the second quarter worth approximately $3,359,000. Jane Street Group LLC grew its stake in shares of Galapagos by 2,245.7% in the first quarter. Jane Street Group LLC now owns 110,783 shares of the biotechnology company’s stock worth $2,783,000 after acquiring an additional 115,946 shares during the period. Finally, 683 Capital Management LLC grew its stake in shares of Galapagos by 57.3% in the first quarter. 683 Capital Management LLC now owns 110,100 shares of the biotechnology company’s stock worth $2,766,000 after acquiring an additional 40,100 shares during the period. 32.46% of the stock is currently owned by institutional investors.

Galapagos Stock Performance

NASDAQ:GLPG opened at $33.04 on Friday. Galapagos has a fifty-two week low of $22.36 and a fifty-two week high of $34.17. The firm has a 50-day simple moving average of $32.38 and a two-hundred day simple moving average of $28.80.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.